Cytokinetics (CYTK) Misses Q4 EPS by 24c

Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.45), $0.24 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $1.96 million versus the consensus estimate of $7.45 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery